Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Current Liabilities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Total Current Liabilities for 13 consecutive years, with $140.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 50.39% to $140.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $140.4 million through Dec 2025, down 50.39% year-over-year, with the annual reading at $140.4 million for FY2025, 50.39% down from the prior year.
  • Total Current Liabilities hit $140.4 million in Q4 2025 for Coherus Oncology, down from $372.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $538.3 million in Q1 2024 to a low of $123.4 million in Q1 2023.
  • Historically, Total Current Liabilities has averaged $255.5 million across 5 years, with a median of $256.3 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 336.2% in 2024 and later crashed 52.62% in 2025.
  • Year by year, Total Current Liabilities stood at $165.3 million in 2021, then dropped by 16.11% to $138.7 million in 2022, then soared by 139.21% to $331.8 million in 2023, then fell by 14.71% to $283.0 million in 2024, then plummeted by 50.39% to $140.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for CHRS at $140.4 million in Q4 2025, $372.3 million in Q3 2025, and $263.6 million in Q2 2025.